🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 04/01/2018 | 153,39 | 153,97 | 151,63 | 153,07 | +0,70% | 1,53% | 1.345.100 |
| 03/01/2018 | 153,50 | 153,50 | 148,58 | 152,01 | -0,59% | 3,21% | 1.604.000 |
| 02/01/2018 | 150,00 | 153,30 | 147,72 | 152,91 | +2,04% | 3,72% | 1.382.000 |
| 29/12/2017 | 150,45 | 151,66 | 149,75 | 149,86 | -0,87% | 1,27% | 881.900 |
| 28/12/2017 | 152,19 | 152,49 | 148,75 | 151,17 | -0,25% | 2,46% | 957.400 |
| 27/12/2017 | 151,13 | 152,70 | 150,30 | 151,55 | +0,63% | 1,59% | 939.100 |
| 26/12/2017 | 149,50 | 151,49 | 149,50 | 150,60 | +0,42% | 1,33% | 777.700 |
| 22/12/2017 | 148,20 | 151,10 | 147,80 | 149,97 | +0,77% | 2,23% | 1.459.200 |
| 21/12/2017 | 145,23 | 149,98 | 144,68 | 148,82 | +2,55% | 3,65% | 2.290.100 |
| 20/12/2017 | 145,05 | 146,26 | 144,36 | 145,12 | -0,02% | 1,31% | 813.600 |
| 19/12/2017 | 145,57 | 147,34 | 144,27 | 145,15 | -0,20% | 2,11% | 1.051.100 |
| 18/12/2017 | 146,99 | 147,94 | 145,17 | 145,44 | -0,29% | 1,88% | 1.231.900 |
| 15/12/2017 | 143,97 | 145,96 | 142,05 | 145,86 | +2,34% | 2,72% | 3.246.100 |
| 14/12/2017 | 145,57 | 146,32 | 142,28 | 142,53 | -1,57% | 2,78% | 1.411.300 |
| 13/12/2017 | 141,93 | 146,36 | 141,55 | 144,80 | +2,76% | 3,39% | 2.024.200 |
| 12/12/2017 | 140,04 | 142,08 | 140,04 | 140,91 | -0,54% | 1,46% | 1.010.200 |
| 11/12/2017 | 143,73 | 143,91 | 139,80 | 141,68 | -1,34% | 2,86% | 1.475.200 |
| 08/12/2017 | 139,80 | 144,80 | 139,11 | 143,61 | +3,48% | 4,07% | 1.725.500 |
| 07/12/2017 | 137,92 | 140,85 | 136,50 | 138,78 | +1,09% | 3,15% | 1.687.500 |
| 06/12/2017 | 138,30 | 139,41 | 136,83 | 137,28 | -0,78% | 1,87% | 1.582.700 |
| 05/12/2017 | 138,60 | 141,67 | 138,02 | 138,36 | -0,31% | 2,63% | 1.374.000 |
| 04/12/2017 | 141,99 | 142,70 | 138,67 | 138,79 | -1,42% | 2,84% | 2.127.700 |
| 01/12/2017 | 143,09 | 144,70 | 139,86 | 140,79 | -2,43% | 3,38% | 2.448.300 |
| 30/11/2017 | 144,19 | 146,10 | 143,95 | 144,29 | +0,38% | 1,49% | 1.739.300 |
| 29/11/2017 | 147,01 | 148,34 | 142,44 | 143,75 | -2,42% | 4,01% | 1.313.900 |
| 28/11/2017 | 148,86 | 149,00 | 146,05 | 147,32 | -0,83% | 1,98% | 1.117.000 |
| 27/11/2017 | 146,84 | 149,29 | 146,72 | 148,55 | +1,36% | 1,75% | 1.197.700 |
| 24/11/2017 | 146,08 | 147,90 | 146,04 | 146,55 | -0,33% | 1,27% | 661.000 |
| 22/11/2017 | 145,42 | 147,39 | 144,81 | 147,04 | +1,33% | 1,77% | 907.000 |
| 21/11/2017 | 145,71 | 146,36 | 143,51 | 145,11 | +0,32% | 1,96% | 1.501.100 |